Clinical trial
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With…
NCT00111956 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00111956 |
|---|---|
| Title | Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome |
| Official title | Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome X |
| Intervention type | Drug |
| Interventions | Etanercept, Placebo |
| Enrollment | 56 |
| Start date | Apr 1, 2004 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | May 27, 2005 |
| Last update posted | Oct 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: